Literature DB >> 24025553

Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Mélanie Saint-Jean1, Gaëlle Quéreux1, Jean-Michel Nguyen2, Lucie Peuvrel1, Anabelle Brocard1, Audrey Vallée3, Anne-Chantal Knol4, Amir Khammari4, Marc G Denis3, Brigitte Dréno5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24025553     DOI： 10.1038/jid.2013.378

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  10 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.

Authors:  Anne Jarry; Damien Masson; Elisabeth Cassagnau; Sigrid Parois; Christian Laboisse; Marc G Denis
Journal:  Mol Cell Probes       Date:  2004-10       Impact factor: 2.365

3.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

4.  BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

Authors:  Maria Colombino; Mariaelena Capone; Amelia Lissia; Antonio Cossu; Corrado Rubino; Vincenzo De Giorgi; Daniela Massi; Ester Fonsatti; Stefania Staibano; Oscar Nappi; Elena Pagani; Milena Casula; Antonella Manca; Mariacristina Sini; Renato Franco; Gerardo Botti; Corrado Caracò; Nicola Mozzillo; Paolo A Ascierto; Giuseppe Palmieri
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

5.  Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.

Authors:  J Lin; Y Goto; H Murata; K Sakaizawa; A Uchiyama; T Saida; M Takata
Journal:  Br J Cancer       Date:  2011-01-11       Impact factor: 7.640

6.  Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.

Authors:  Johanne Lade-Keller; Kirsten M Rømer; Per Guldberg; Rikke Riber-Hansen; Lise Lotte Hansen; Torben Steiniche; Henrik Hager; Lasse S Kristensen
Journal:  J Mol Diagn       Date:  2012-11-14       Impact factor: 5.568

Review 7.  BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.

Authors:  D Gonzalez; L Fearfield; P Nathan; P Tanière; A Wallace; E Brown; C Harwood; J Marsden; S Whittaker
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

9.  Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

Authors:  Molly Yancovitz; Adam Litterman; Joanne Yoon; Elise Ng; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Farbod Darvishian; Paul Christos; Madhu Mazumdar; Iman Osman; David Polsky
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

10.  Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.

Authors:  Nicola L Schoenewolf; Reinhard Dummer; Daniela Mihic-Probst; Holger Moch; Mathew Simcock; Adrian Ochsenbein; Silke Gillessen; Peter Schraml; Roger von Moos
Journal:  Case Rep Oncol       Date:  2012-06-05
  10 in total
  15 in total

1.  To B-(RAF) or not to be.

Authors:  Reinhard Dummer; Simone M Goldinger; Daniel Widmer; Jil Dreier; Mitchell P Levesque
Journal:  J Invest Dermatol       Date:  2014-05       Impact factor: 8.551

2.  Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors.

Authors:  Erica Riveiro-Falkenbach; Cándida A Villanueva; María C Garrido; Yolanda Ruano; Rosa M García-Martín; Elena Godoy; Pablo L Ortiz-Romero; Juan J Ríos-Martín; Angel Santos-Briz; José L Rodríguez-Peralto
Journal:  J Invest Dermatol       Date:  2015-06-17       Impact factor: 8.551

Review 3.  Heterogeneity in Melanoma.

Authors:  Mei Fong Ng; Jacinta L Simmons; Glen M Boyle
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

4.  Mutational Heterogeneity in Melanoma: An Inconvenient Truth.

Authors:  Gregory A Chang; David Polsky
Journal:  J Invest Dermatol       Date:  2015-12       Impact factor: 8.551

5.  Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR.

Authors:  Atsuko Ashida; Kaori Sakaizawa; Asuka Mikoshiba; Hisashi Uhara; Ryuhei Okuyama
Journal:  Int J Clin Oncol       Date:  2016-04-04       Impact factor: 3.402

Review 6.  Somatic DNA mutation analysis in targeted therapy of solid tumours.

Authors:  Bing Yu; Sandra A O'Toole; Ronald J Trent
Journal:  Transl Pediatr       Date:  2015-04

Review 7.  BRAF Heterogeneity in Melanoma.

Authors:  Takamichi Ito; Yuka Tanaka; Maho Murata; Yumiko Kaku-Ito; Kazuhisa Furue; Masutaka Furue
Journal:  Curr Treat Options Oncol       Date:  2021-02-08

8.  Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model.

Authors:  Shuyang S Qin; Booyeon J Han; Alyssa Williams; Katherine M Jackson; Rachel Jewell; Alexander C Chacon; Edith M Lord; David C Linehan; Minsoo Kim; Alexandre Reuben; Scott A Gerber; Peter A Prieto
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 9.  Treating advanced melanoma: current insights and opportunities.

Authors:  Michael Tronnier; Christina Mitteldorf
Journal:  Cancer Manag Res       Date:  2014-09-10       Impact factor: 3.989

10.  Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

Authors:  A M Menzies; J S Wilmott; G V Long; R A Scolyer
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.